Alector Inc. (NASDAQ: ALEC) announced it will discontinue its Phase 2 PROGRESS-AD trial of nivisnebart in early Alzheimer's disease following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE